Mass spectrometric detection of peginesatide in human urine in doping control analysis

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 512-517

  Möller, Ines ^a   Thomas, Andreas ^a   Delahaut, Philippe ^b   Geyer, Hans ^a   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b CER Groupe Dé partement Santé   (Belgium)

Author keywords

Doping; Erythropoiesis stimulating agents; Hematide; Omontys; Peginesatide; Sport

Indexed keywords

PEGINESATIDE;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPING; DRUG DETERMINATION; DRUG URINE LEVEL; FEMALE; HUMAN; IN VIVO STUDY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; RAT; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDITY;

ACETONITRILES; ANIMALS; CALIBRATION; CATION EXCHANGE RESINS; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; DRUG STABILITY; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; LIMIT OF DETECTION; LINEAR MODELS; PEPTIDES; PERFORMANCE-ENHANCING SUBSTANCES; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84866238386     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.07.022     Document Type: Article

References (18)

1. Affymax Affymax and Takeda Announce FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on Dialysis 2012, Affymax Inc, (accessed April 2012). http://www.investors.affymax.com/releasedetail.cfm%3FReleaseID=659811.
2. Woodburn K.W., Holmes C.P., Wilson S.D., Fong K.L., Press R.J., Moriya Y., Tagawa Y. Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica 2012, 42:660-670.
3. Macdougall I.C. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr. Opin. Investig. Drugs 2008, 9:1034-1047.
4. Woo S., Krzyzanski W., Duliege A.M., Stead R.B., Jusko W.J. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J. Clin. Pharmacol. 2008, 48:43-52.
5. Fan Q., Leuther K.K., Holmes C.P., Fong K.L., Zhang J., Velkovska S., Chen M.J., Mortensen R.B., Leu K., Green J.M., Schatz P.J., Woodburn K.W. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp. Hematol. 2006, 34:1303-1311.
6. Stead R.B., Lambert J., Wessels D., Iwashita J.S., Leuther K.K., Woodburn K.W., Schatz P.J., Okamoto D.M., Naso R., Duliege A.M. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006, 108:1830-1834.
7. Macdougall I.C., Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv. Chronic Kidney Dis. 2009, 16:117-130.
8. Doss S., Schiller B. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure. Nephrol. Nurs. J. 2010, 37:617-626.
9. Locatelli F., Del Vecchio L. Hematide™ for the treatment of chronic kidney disease-related anemia. Expert Rev. Hematol. 2009, 2:377-383.
10. Macdougall I.C. New anemia therapies: translating novel strategies from bench to bedside. Am. J. Kidney Dis. 2012, 59:444-451.
11. Thevis M., Thomas A., Kohler M., Beuck S., Schänzer W. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J. Mass Spectrom. 2009, 44:442-460.
12. WADA The 2009 Prohibited List 2008, WADA (World Anti-Doping Agency), (accessed May 2012). http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_%20Sept_08.pdf.
13. Möller I., Thomas A., Geyer H., Schänzer W., Thevis M. Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Commun. Mass Spectrom. 2011, 25:2115-2123.
14. Möller I., Thomas A., Geyer H., Schänzer W., Thevis M. Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. Anal. Bioanal. Chem. 2012, 10.1007/s00216-012-6043-2.
15. Leuenberger M., Saugy J., Mortensen R.B., Schatz P., Giraud S., Saugy M. Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples. Forensic Sci. Int. 2011, 213:15-19.
16. 14C-Peginesatide clearance, metabolism, and excretion in monkeys following IV administration, poster presentation American Society of Nephrology annual meeting (2010) Denver, Colorado, USA. Abstract SA-PO2584. J. Am. Soc. Nephrol. 2010, 21:703A.
17. ICH Validation of Analytical Procedures: Text and Methodology Q2(R1). ICH (International Conference on Harmonisation) 2005, Accessed January 2012. http://www.ich.org/fileadmin/Public%20_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
18. Bonfiglio R., King R.C., Olah T.V., Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13:1175-1185.